Related Experiment Video

Updated: Jul 17, 2026

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Antiangiogenesis to treat cancer and intraocular neovascular disorders

Farbod Shojaei1, Napoleone Ferrara

  • 1Genentech Inc., South San Francisco, CA 94080, USA.

Laboratory Investigation; a Journal of Technical Methods and Pathology
|January 30, 2007
PubMed

Insights

New antiangiogenic drugs targeting vascular endothelial growth factor-A (VEGF-A) offer novel cancer and macular degeneration therapies. This review examines VEGF-A targeting and resistance mechanisms in antiangiogenic treatments.

Area of Science:

  • Biomedical Science
  • Oncology
  • Ophthalmology

Background:

  • Angiogenesis regulators and antiangiogenic drugs have revolutionized cancer and neovascular age-related macular degeneration treatment.
  • Vascular Endothelial Growth Factor-A (VEGF-A) is a key regulator of angiogenesis.

Purpose of the Study:

  • To review progress in targeting VEGF-A for antiangiogenic therapies.
  • To discuss cellular and molecular mechanisms of resistance to antiangiogenic treatments.

Main Methods:

  • Literature review of angiogenesis research.
  • Analysis of clinical data on antiangiogenic drug efficacy.
  • Exploration of molecular pathways involved in treatment resistance.

Main Results:

  • Significant advancements have been made in targeting VEGF-A.
  • Several antiangiogenic drugs are FDA-approved for specific conditions.
  • Mechanisms of resistance to antiangiogenic therapy are being elucidated.

Conclusions:

  • Targeting VEGF-A represents a major therapeutic strategy.
  • Understanding resistance mechanisms is crucial for improving antiangiogenic treatments.
  • Further research is needed to overcome resistance and enhance treatment outcomes.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...